Global Gestational Trophoblastic Disease Market-Industry Analysis and forecast 2019 – 2027 -By Type, Treatment, End-User, and Region.

Global Gestational Trophoblastic Disease Market-Industry Analysis and forecast 2019 – 2027 -By Type, Treatment, End-User, and Region.

Market Scenario

Global Gestational Trophoblastic Disease Market size was valued US$ XX Mn. in 2019 and the total revenue is expected to grow at 4.10% through 2019 to 2027, reaching nearly US$ XX Mn.   Global Gestational Trophoblastic Disease Market The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis. Gestational trophoblastic disease (GTD) is a spectrum of diseases that affect women mostly of reproductive age. Gestational trophoblastic disease entities are derived from placental origin, ranging from abnormal products of conception with malignant potential to malignant gestational trophoblastic neoplasia (GTN). The report analyzes various factors which have been driving the global trophoblastic disease market in the past. Also, the MMR report analyzes the impact of each driver and restraint on the market growth, which forms the base for market forecast. The report also showcases the opportunities available in the trophoblastic disease market which may act as future drivers for the market. Such as, upsurge in risk factors affecting this spectrum of disease is expected to fuel the growth of the market. These risk factors contain the rise in ectopic pregnancies, high maternal age, and excessive smoking. As per the American Lung Association, cigarette smoking kills an expected 201,770 women annually in the U.S. Also, the growing innovations in the field of oncology in expected contributing significantly to the growth in GTD market globally. Such as, in 2018 Bristol-Myers Squibb Company announced a clinical collaboration to evaluate therapeutic regimen in advanced solid tumors. On the Other hand, high risk of repetition of the tumors, even after multi or single-agent chemotherapy and difficulty in diagnosing the types of hydatidiform moles may hinder the GTD market growth. The report covers the segments in the gestational trophoblastic disease market such as type, treatment, and end user. By type, the hydatidiform mole segment is expected to continue to hold the largest XX.17% share in the gestational trophoblastic disease market because of most common form of the gestational trophoblastic disease. North America gestational trophoblastic disease market was valued at US$ XX.02 Mn. in 2019 and is expected to reach a value of US$ XX.19 Mn. by 2027, with a CAGR of XX.53% during the forecast period. This is because of an increased awareness about the disease and favorable reimbursement scenario. Also, the upsurge in many marketing approvals, as well as product approvals in the field of oncology drives the GTD market growth. On the other hand, the MEA has the least share of the gestational trophoblastic disease market due to the lack of technical expertise and stringent government regulations in the treatment of the disease. In recent years, major companies in the gestational trophoblastic disease market have taken various strategic measures, like facility expansions and partnerships. Such as, in 2018, Novartis AG Company entered into a license and collaboration agreement with Cellular Biomedicine Group, a clinical stage biopharmaceutical company which improves therapies for cancer and degenerative diseases in China. The objective of the report is to present a comprehensive analysis of the Global Gestational Trophoblastic Disease Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Gestational Trophoblastic Disease Market dynamics, structure by analyzing the market segments and projects the Global Gestational Trophoblastic Disease Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Gestational Trophoblastic Disease Market make the report investor’s guide.

Scope of the Global Gestational Trophoblastic Disease Market

Global Gestational Trophoblastic Disease Market, by Type

• Hydatidiform mole o Complete o Partial o Invasive • Choriocarcinoma • Placental-site trophoblastic tumor • Epithelioid trophoblastic tumor • Others

Global Gestational Trophoblastic Disease Market, by Treatment

• Surgery o Abdominal hysterectomy o Vaginal hysterectomy • Chemotherapy • Suction dilation and curettage (D&C) • Radiation Therapy

Global Gestational Trophoblastic Disease Market, by End user

• Hospital and clinics • Diagnostic centers • Others

Global Gestational Trophoblastic Disease Market, by Region

• Asia Pacific • North America • Europe • South America • Middle East & Africa

Key players operating in the Global Gestational Trophoblastic Disease Market

• Hikma Pharmaceuticals PLC • Pfizer Inc. • Bristol-Myers Squibb Company • Antares Pharma • Mylan N.V. • Novartis AG • Teva Pharmaceutical Industries Ltd. • BP Pharmaceuticals Laboratories Company • Fresenius Kabi AG • Accord Healthcare, Inc. • Eli Lilly and Company • Sanofi • Bayer AG • Amgen Inc. • Merck

Table of Contents

Global Gestational Trophoblastic Disease Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Gestational Trophoblastic Disease Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Gestational Trophoblastic Disease Market Analysis and Forecast 6.1. Gestational Trophoblastic Disease Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Gestational Trophoblastic Disease Market Analysis and Forecast, By Treatment 7.1. Introduction and Definition 7.2. Key Findings 7.3. Gestational Trophoblastic Disease Market Value Share Analysis, By Treatment 7.4. Gestational Trophoblastic Disease Market Size (US$ Bn) Forecast, By Treatment 7.5. Gestational Trophoblastic Disease Market Analysis, By Treatment 7.6. Gestational Trophoblastic Disease Market Attractiveness Analysis, By Treatment 8. Global Gestational Trophoblastic Disease Market Analysis and Forecast, By End User 8.1. Introduction and Definition 8.2. Key Findings 8.3. Gestational Trophoblastic Disease Market Value Share Analysis, By End User 8.4. Gestational Trophoblastic Disease Market Size (US$ Bn) Forecast, By End User 8.5. Gestational Trophoblastic Disease Market Analysis, By End User 8.6. Gestational Trophoblastic Disease Market Attractiveness Analysis, By End User 9. Global Gestational Trophoblastic Disease Market Analysis and Forecast, By Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Gestational Trophoblastic Disease Market Value Share Analysis, By Type 9.4. Gestational Trophoblastic Disease Market Size (US$ Bn) Forecast, By Type 9.5. Gestational Trophoblastic Disease Market Analysis, By Type 9.6. Gestational Trophoblastic Disease Market Attractiveness Analysis, By Type 10. Global Gestational Trophoblastic Disease Market Analysis, by Region 10.1. Gestational Trophoblastic Disease Market Value Share Analysis, by Region 10.2. Gestational Trophoblastic Disease Market Size (US$ Bn) Forecast, by Region 10.3. Gestational Trophoblastic Disease Market Attractiveness Analysis, by Region 11. North America Gestational Trophoblastic Disease Market Analysis 11.1. Key Findings 11.2. North America Gestational Trophoblastic Disease Market Overview 11.3. North America Gestational Trophoblastic Disease Market Value Share Analysis, By Treatment 11.4. North America Gestational Trophoblastic Disease Market Forecast, By Treatment 11.4.1. Surgery 11.4.1.1. Abdominal hysterectomy 11.4.1.2. Vaginal hysterectomy 11.4.2. Chemotherapy 11.4.3. Suction dilation and curettage (D&C) 11.4.4. Radiation Therapy 11.5. North America Gestational Trophoblastic Disease Market Value Share Analysis, By End User 11.6. North America Gestational Trophoblastic Disease Market Forecast, By End User 11.6.1. Hospital and clinics 11.6.2. Diagnostic centers 11.6.3. Others 11.7. North America Gestational Trophoblastic Disease Market Value Share Analysis, By Type 11.8. North America Gestational Trophoblastic Disease Market Forecast, By Type 11.8.1. Hydatidiform mole 11.8.1.1. Complete 11.8.1.2. Partial 11.8.1.3. Invasive 11.8.2. Choriocarcinoma 11.8.3. Placental-site trophoblastic tumor 11.8.4. Epithelioid trophoblastic tumor 11.8.5. Others 11.9. North America Gestational Trophoblastic Disease Market Value Share Analysis, by Country 11.10. North America Gestational Trophoblastic Disease Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Gestational Trophoblastic Disease Market Analysis, by Country 11.12. U.S. Gestational Trophoblastic Disease Market Forecast, By Treatment 11.12.1. Surgery 11.12.1.1. Abdominal hysterectomy 11.12.1.2. Vaginal hysterectomy 11.12.2. Chemotherapy 11.12.3. Suction dilation and curettage (D&C) 11.12.4. Radiation Therapy 11.13. U.S. Gestational Trophoblastic Disease Market Forecast, By End User 11.13.1. Hospital and clinics 11.13.2. Diagnostic centers 11.13.3. Others 11.14. U.S. Gestational Trophoblastic Disease Market Forecast, By Type 11.14.1. Hydatidiform mole 11.14.1.1. Complete 11.14.1.2. Partial 11.14.1.3. Invasive 11.14.2. Choriocarcinoma 11.14.3. Placental-site trophoblastic tumor 11.14.4. Epithelioid trophoblastic tumor 11.14.5. Others 11.15. Canada Gestational Trophoblastic Disease Market Forecast, By Treatment 11.15.1. Surgery 11.15.1.1. Abdominal hysterectomy 11.15.1.2. Vaginal hysterectomy 11.15.2. Chemotherapy 11.15.3. Suction dilation and curettage (D&C) 11.15.4. Radiation Therapy 11.16. Canada Gestational Trophoblastic Disease Market Forecast, By End User 11.16.1. Hospital and clinics 11.16.2. Diagnostic centers 11.16.3. Others 11.17. Canada Gestational Trophoblastic Disease Market Forecast, By Type 11.17.1. Hydatidiform mole 11.17.1.1. Complete 11.17.1.2. Partial 11.17.1.3. Invasive 11.17.2. Choriocarcinoma 11.17.3. Placental-site trophoblastic tumor 11.17.4. Epithelioid trophoblastic tumor 11.17.5. Others 11.18. North America Gestational Trophoblastic Disease Market Attractiveness Analysis 11.18.1. By Treatment 11.18.2. By End User 11.18.3. By Type 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Gestational Trophoblastic Disease Market Analysis 12.1. Key Findings 12.2. Europe Gestational Trophoblastic Disease Market Overview 12.3. Europe Gestational Trophoblastic Disease Market Value Share Analysis, By Treatment 12.4. Europe Gestational Trophoblastic Disease Market Forecast, By Treatment 12.4.1. Surgery 12.4.1.1. Abdominal hysterectomy 12.4.1.2. Vaginal hysterectomy 12.4.2. Chemotherapy 12.4.3. Suction dilation and curettage (D&C) 12.4.4. Radiation Therapy 12.5. Europe Gestational Trophoblastic Disease Market Value Share Analysis, By End User 12.6. Europe Gestational Trophoblastic Disease Market Forecast, By End User 12.6.1. Hospital and clinics 12.6.2. Diagnostic centers 12.6.3. Others 12.7. Europe Gestational Trophoblastic Disease Market Value Share Analysis, By Type 12.8. Europe Gestational Trophoblastic Disease Market Forecast, By Type 12.8.1. Hydatidiform mole 12.8.1.1. Complete 12.8.1.2. Partial 12.8.1.3. Invasive 12.8.2. Choriocarcinoma 12.8.3. Placental-site trophoblastic tumor 12.8.4. Epithelioid trophoblastic tumor 12.8.5. Others 12.9. Europe Gestational Trophoblastic Disease Market Value Share Analysis, by Country 12.10. Europe Gestational Trophoblastic Disease Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Gestational Trophoblastic Disease Market Analysis, by Country 12.12. Germany Gestational Trophoblastic Disease Market Forecast, By Treatment 12.12.1. Surgery 12.12.1.1. Abdominal hysterectomy 12.12.1.2. Vaginal hysterectomy 12.12.2. Chemotherapy 12.12.3. Suction dilation and curettage (D&C) 12.12.4. Radiation Therapy 12.13. Germany Gestational Trophoblastic Disease Market Forecast, By End User 12.13.1. Hospital and clinics 12.13.2. Diagnostic centers 12.13.3. Others 12.14. Germany Gestational Trophoblastic Disease Market Forecast, By Type 12.14.1. Hydatidiform mole 12.14.1.1. Complete 12.14.1.2. Partial 12.14.1.3. Invasive 12.14.2. Choriocarcinoma 12.14.3. Placental-site trophoblastic tumor 12.14.4. Epithelioid trophoblastic tumor 12.14.5. Others 12.15. U.K. Gestational Trophoblastic Disease Market Forecast, By Treatment 12.15.1. Surgery 12.15.1.1. Abdominal hysterectomy 12.15.1.2. Vaginal hysterectomy 12.15.2. Chemotherapy 12.15.3. Suction dilation and curettage (D&C) 12.15.4. Radiation Therapy 12.16. U.K. Gestational Trophoblastic Disease Market Forecast, By End User 12.16.1. Hospital and clinics 12.16.2. Diagnostic centers 12.16.3. Others 12.17. U.K. Gestational Trophoblastic Disease Market Forecast, By Type 12.17.1. Hydatidiform mole 12.17.1.1. Complete 12.17.1.2. Partial 12.17.1.3. Invasive 12.17.2. Choriocarcinoma 12.17.3. Placental-site trophoblastic tumor 12.17.4. Epithelioid trophoblastic tumor 12.17.5. Others 12.18. France Gestational Trophoblastic Disease Market Forecast, By Treatment 12.18.1. Surgery 12.18.1.1. Abdominal hysterectomy 12.18.1.2. Vaginal hysterectomy 12.18.2. Chemotherapy 12.18.3. Suction dilation and curettage (D&C) 12.18.4. Radiation Therapy 12.19. France Gestational Trophoblastic Disease Market Forecast, By End User 12.19.1. Hospital and clinics 12.19.2. Diagnostic centers 12.19.3. Others 12.20. France Gestational Trophoblastic Disease Market Forecast, By Type 12.20.1. Hydatidiform mole 12.20.1.1. Complete 12.20.1.2. Partial 12.20.1.3. Invasive 12.20.2. Choriocarcinoma 12.20.3. Placental-site trophoblastic tumor 12.20.4. Epithelioid trophoblastic tumor 12.20.5. Others 12.21. Italy Gestational Trophoblastic Disease Market Forecast, By Treatment 12.21.1. Surgery 12.21.1.1. Abdominal hysterectomy 12.21.1.2. Vaginal hysterectomy 12.21.2. Chemotherapy 12.21.3. Suction dilation and curettage (D&C) 12.21.4. Radiation Therapy 12.22. Italy Gestational Trophoblastic Disease Market Forecast, By End User 12.22.1. Hospital and clinics 12.22.2. Diagnostic centers 12.22.3. Others 12.23. Italy Gestational Trophoblastic Disease Market Forecast, By Type 12.23.1. Hydatidiform mole 12.23.1.1. Complete 12.23.1.2. Partial 12.23.1.3. Invasive 12.23.2. Choriocarcinoma 12.23.3. Placental-site trophoblastic tumor 12.23.4. Epithelioid trophoblastic tumor 12.23.5. Others 12.24. Spain Gestational Trophoblastic Disease Market Forecast, By Treatment 12.24.1. Surgery 12.24.1.1. Abdominal hysterectomy 12.24.1.2. Vaginal hysterectomy 12.24.2. Chemotherapy 12.24.3. Suction dilation and curettage (D&C) 12.24.4. Radiation Therapy 12.25. Spain Gestational Trophoblastic Disease Market Forecast, By End User 12.25.1. Hospital and clinics 12.25.2. Diagnostic centers 12.25.3. Others 12.26. Spain Gestational Trophoblastic Disease Market Forecast, By Type 12.26.1. Hydatidiform mole 12.26.1.1. Complete 12.26.1.2. Partial 12.26.1.3. Invasive 12.26.2. Choriocarcinoma 12.26.3. Placental-site trophoblastic tumor 12.26.4. Epithelioid trophoblastic tumor 12.26.5. Others 12.27. Rest of Europe Gestational Trophoblastic Disease Market Forecast, By Treatment 12.27.1. Surgery 12.27.1.1. Abdominal hysterectomy 12.27.1.2. Vaginal hysterectomy 12.27.2. Chemotherapy 12.27.3. Suction dilation and curettage (D&C) 12.27.4. Radiation Therapy 12.28. Rest of Europe Gestational Trophoblastic Disease Market Forecast, By End User 12.28.1. Hospital and clinics 12.28.2. Diagnostic centers 12.28.3. Others 12.29. Rest Of Europe Gestational Trophoblastic Disease Market Forecast, By Type 12.29.1. Hydatidiform mole 12.29.1.1. Complete 12.29.1.2. Partial 12.29.1.3. Invasive 12.29.2. Choriocarcinoma 12.29.3. Placental-site trophoblastic tumor 12.29.4. Epithelioid trophoblastic tumor 12.29.5. Others 12.30. Europe Gestational Trophoblastic Disease Market Attractiveness Analysis 12.30.1. By Treatment 12.30.2. By End User 12.30.3. By Type 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Gestational Trophoblastic Disease Market Analysis 13.1. Key Findings 13.2. Asia Pacific Gestational Trophoblastic Disease Market Overview 13.3. Asia Pacific Gestational Trophoblastic Disease Market Value Share Analysis, By Treatment 13.4. Asia Pacific Gestational Trophoblastic Disease Market Forecast, By Treatment 13.4.1. Surgery 13.4.1.1. Abdominal hysterectomy 13.4.1.2. Vaginal hysterectomy 13.4.2. Chemotherapy 13.4.3. Suction dilation and curettage (D&C) 13.4.4. Radiation Therapy 13.5. Asia Pacific Gestational Trophoblastic Disease Market Value Share Analysis, By End User 13.6. Asia Pacific Gestational Trophoblastic Disease Market Forecast, By End User 13.6.1. Hospital and clinics 13.6.2. Diagnostic centers 13.6.3. Others 13.7. Asia Pacific Gestational Trophoblastic Disease Market Value Share Analysis, By Type 13.8. Asia Pacific Gestational Trophoblastic Disease Market Forecast, By Type 13.8.1. Hydatidiform mole 13.8.1.1. Complete 13.8.1.2. Partial 13.8.1.3. Invasive 13.8.2. Choriocarcinoma 13.8.3. Placental-site trophoblastic tumor 13.8.4. Epithelioid trophoblastic tumor 13.8.5. Others 13.9. Asia Pacific Gestational Trophoblastic Disease Market Value Share Analysis, by Country 13.10. Asia Pacific Gestational Trophoblastic Disease Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Gestational Trophoblastic Disease Market Analysis, by Country 13.12. China Gestational Trophoblastic Disease Market Forecast, By Treatment 13.12.1. Surgery 13.12.1.1. Abdominal hysterectomy 13.12.1.2. Vaginal hysterectomy 13.12.2. Chemotherapy 13.12.3. Suction dilation and curettage (D&C) 13.12.4. Radiation Therapy 13.13. China Gestational Trophoblastic Disease Market Forecast, By End User 13.13.1. Hospital and clinics 13.13.2. Diagnostic centers 13.13.3. Others 13.14. China Gestational Trophoblastic Disease Market Forecast, By Type 13.14.1. Hydatidiform mole 13.14.1.1. Complete 13.14.1.2. Partial 13.14.1.3. Invasive 13.14.2. Choriocarcinoma 13.14.3. Placental-site trophoblastic tumor 13.14.4. Epithelioid trophoblastic tumor 13.14.5. Others 13.15. India Gestational Trophoblastic Disease Market Forecast, By Treatment 13.15.1. Surgery 13.15.1.1. Abdominal hysterectomy 13.15.1.2. Vaginal hysterectomy 13.15.2. Chemotherapy 13.15.3. Suction dilation and curettage (D&C) 13.15.4. Radiation Therapy 13.16. India Gestational Trophoblastic Disease Market Forecast, By End User 13.16.1. Hospital and clinics 13.16.2. Diagnostic centers 13.16.3. Others 13.17. India Gestational Trophoblastic Disease Market Forecast, By Type 13.17.1. Hydatidiform mole 13.17.1.1. Complete 13.17.1.2. Partial 13.17.1.3. Invasive 13.17.2. Choriocarcinoma 13.17.3. Placental-site trophoblastic tumor 13.17.4. Epithelioid trophoblastic tumor 13.17.5. Others 13.18. Japan Gestational Trophoblastic Disease Market Forecast, By Treatment 13.18.1. Surgery 13.18.1.1. Abdominal hysterectomy 13.18.1.2. Vaginal hysterectomy 13.18.2. Chemotherapy 13.18.3. Suction dilation and curettage (D&C) 13.18.4. Radiation Therapy 13.19. Japan Gestational Trophoblastic Disease Market Forecast, By End User 13.19.1. Hospital and clinics 13.19.2. Diagnostic centers 13.19.3. Others 13.20. Japan Gestational Trophoblastic Disease Market Forecast, By Type 13.20.1. Hydatidiform mole 13.20.1.1. Complete 13.20.1.2. Partial 13.20.1.3. Invasive 13.20.2. Choriocarcinoma 13.20.3. Placental-site trophoblastic tumor 13.20.4. Epithelioid trophoblastic tumor 13.20.5. Others 13.21. ASEAN Gestational Trophoblastic Disease Market Forecast, By Treatment 13.21.1. Surgery 13.21.1.1. Abdominal hysterectomy 13.21.1.2. Vaginal hysterectomy 13.21.2. Chemotherapy 13.21.3. Suction dilation and curettage (D&C) 13.21.4. Radiation Therapy 13.22. ASEAN Gestational Trophoblastic Disease Market Forecast, By End User 13.22.1. Hospital and clinics 13.22.2. Diagnostic centers 13.22.3. Others 13.23. ASEAN Gestational Trophoblastic Disease Market Forecast, By Type 13.23.1. Hydatidiform mole 13.23.1.1. Complete 13.23.1.2. Partial 13.23.1.3. Invasive 13.23.2. Choriocarcinoma 13.23.3. Placental-site trophoblastic tumor 13.23.4. Epithelioid trophoblastic tumor 13.23.5. Others 13.24. Rest of Asia Pacific Gestational Trophoblastic Disease Market Forecast, By Treatment 13.24.1. Surgery 13.24.1.1. Abdominal hysterectomy 13.24.1.2. Vaginal hysterectomy 13.24.2. Chemotherapy 13.24.3. Suction dilation and curettage (D&C) 13.24.4. Radiation Therapy 13.25. Rest of Asia Pacific Gestational Trophoblastic Disease Market Forecast, By End User 13.25.1. Hospital and clinics 13.25.2. Diagnostic centers 13.25.3. Others 13.26. Rest of Asia Pacific Gestational Trophoblastic Disease Market Forecast, By Type 13.26.1. Hydatidiform mole 13.26.1.1. Complete 13.26.1.2. Partial 13.26.1.3. Invasive 13.26.2. Choriocarcinoma 13.26.3. Placental-site trophoblastic tumor 13.26.4. Epithelioid trophoblastic tumor 13.26.5. Others 13.27. Asia Pacific Gestational Trophoblastic Disease Market Attractiveness Analysis 13.27.1. By Treatment 13.27.2. By End User 13.27.3. By Type 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Gestational Trophoblastic Disease Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Gestational Trophoblastic Disease Market Overview 14.3. Middle East & Africa Gestational Trophoblastic Disease Market Value Share Analysis, By Treatment 14.4. Middle East & Africa Gestational Trophoblastic Disease Market Forecast, By Treatment 14.4.1. Surgery 14.4.1.1. Abdominal hysterectomy 14.4.1.2. Vaginal hysterectomy 14.4.2. Chemotherapy 14.4.3. Suction dilation and curettage (D&C) 14.4.4. Radiation Therapy 14.5. Middle East & Africa Gestational Trophoblastic Disease Market Value Share Analysis, By End User 14.6. Middle East & Africa Gestational Trophoblastic Disease Market Forecast, By End User 14.6.1. Hospital and clinics 14.6.2. Diagnostic centers 14.6.3. Others 14.7. Middle East & Africa Gestational Trophoblastic Disease Market Value Share Analysis, By Type 14.8. Middle East & Africa Gestational Trophoblastic Disease Market Forecast, By Type 14.8.1. Hydatidiform mole 14.8.1.1. Complete 14.8.1.2. Partial 14.8.1.3. Invasive 14.8.2. Choriocarcinoma 14.8.3. Placental-site trophoblastic tumor 14.8.4. Epithelioid trophoblastic tumor 14.8.5. Others 14.9. Middle East & Africa Gestational Trophoblastic Disease Market Value Share Analysis, by Country 14.10. Middle East & Africa Gestational Trophoblastic Disease Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Gestational Trophoblastic Disease Market Analysis, by Country 14.12. GCC Gestational Trophoblastic Disease Market Forecast, By Treatment 14.12.1. Surgery 14.12.1.1. Abdominal hysterectomy 14.12.1.2. Vaginal hysterectomy 14.12.2. Chemotherapy 14.12.3. Suction dilation and curettage (D&C) 14.12.4. Radiation Therapy 14.13. GCC Gestational Trophoblastic Disease Market Forecast, By End User 14.13.1. Hospital and clinics 14.13.2. Diagnostic centers 14.13.3. Others 14.14. GCC Gestational Trophoblastic Disease Market Forecast, By Type 14.14.1. Hydatidiform mole 14.14.1.1. Complete 14.14.1.2. Partial 14.14.1.3. Invasive 14.14.2. Choriocarcinoma 14.14.3. Placental-site trophoblastic tumor 14.14.4. Epithelioid trophoblastic tumor 14.14.5. Others 14.15. South Africa Gestational Trophoblastic Disease Market Forecast, By Treatment 14.15.1. Surgery 14.15.1.1. Abdominal hysterectomy 14.15.1.2. Vaginal hysterectomy 14.15.2. Chemotherapy 14.15.3. Suction dilation and curettage (D&C) 14.15.4. Radiation Therapy 14.16. South Africa Gestational Trophoblastic Disease Market Forecast, By End User 14.16.1. Hospital and clinics 14.16.2. Diagnostic centers 14.16.3. Others 14.17. South Africa Gestational Trophoblastic Disease Market Forecast, By Type 14.17.1. Hydatidiform mole 14.17.1.1. Complete 14.17.1.2. Partial 14.17.1.3. Invasive 14.17.2. Choriocarcinoma 14.17.3. Placental-site trophoblastic tumor 14.17.4. Epithelioid trophoblastic tumor 14.17.5. Others 14.18. Rest of Middle East & Africa Gestational Trophoblastic Disease Market Forecast, By Treatment 14.18.1. Surgery 14.18.1.1. Abdominal hysterectomy 14.18.1.2. Vaginal hysterectomy 14.18.2. Chemotherapy 14.18.3. Suction dilation and curettage (D&C) 14.18.4. Radiation Therapy 14.19. Rest of Middle East & Africa Gestational Trophoblastic Disease Market Forecast, By End User 14.19.1. Hospital and clinics 14.19.2. Diagnostic centers 14.19.3. Others 14.20. Middle East & Africa Gestational Trophoblastic Disease Market Forecast, By Type 14.20.1. Hydatidiform mole 14.20.1.1. Complete 14.20.1.2. Partial 14.20.1.3. Invasive 14.20.2. Choriocarcinoma 14.20.3. Placental-site trophoblastic tumor 14.20.4. Epithelioid trophoblastic tumor 14.20.5. Others 14.21. Middle East & Africa Gestational Trophoblastic Disease Market Attractiveness Analysis 14.21.1. By Treatment 14.21.2. By End User 14.21.3. By Type 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Gestational Trophoblastic Disease Market Analysis 15.1. Key Findings 15.2. South America Gestational Trophoblastic Disease Market Overview 15.3. South America Gestational Trophoblastic Disease Market Value Share Analysis, By Treatment 15.4. South America Gestational Trophoblastic Disease Market Forecast, By Treatment 15.4.1. Surgery 15.4.1.1. Abdominal hysterectomy 15.4.1.2. Vaginal hysterectomy 15.4.2. Chemotherapy 15.4.3. Suction dilation and curettage (D&C) 15.4.4. Radiation Therapy 15.5. South America Gestational Trophoblastic Disease Market Value Share Analysis, By End User 15.6. South America Gestational Trophoblastic Disease Market Forecast, By End User 15.6.1. Hospital and clinics 15.6.2. Diagnostic centers 15.6.3. Others 15.7. South America Gestational Trophoblastic Disease Market Value Share Analysis, By Type 15.8. South America Gestational Trophoblastic Disease Market Forecast, By Type 15.8.1. Hydatidiform mole 15.8.1.1. Complete 15.8.1.2. Partial 15.8.1.3. Invasive 15.8.2. Choriocarcinoma 15.8.3. Placental-site trophoblastic tumor 15.8.4. Epithelioid trophoblastic tumor 15.8.5. Others 15.9. South America Gestational Trophoblastic Disease Market Value Share Analysis, by Country 15.10. South America Gestational Trophoblastic Disease Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Gestational Trophoblastic Disease Market Analysis, by Country 15.12. Brazil Gestational Trophoblastic Disease Market Forecast, By Treatment 15.12.1. Surgery 15.12.1.1. Abdominal hysterectomy 15.12.1.2. Vaginal hysterectomy 15.12.2. Chemotherapy 15.12.3. Suction dilation and curettage (D&C) 15.12.4. Radiation Therapy 15.13. Brazil Gestational Trophoblastic Disease Market Forecast, By End User 15.13.1. Hospital and clinics 15.13.2. Diagnostic centers 15.13.3. Others 15.14. Brazil Gestational Trophoblastic Disease Market Forecast, By Type 15.14.1. Hydatidiform mole 15.14.1.1. Complete 15.14.1.2. Partial 15.14.1.3. Invasive 15.14.2. Choriocarcinoma 15.14.3. Placental-site trophoblastic tumor 15.14.4. Epithelioid trophoblastic tumor 15.14.5. Others 15.15. Mexico Gestational Trophoblastic Disease Market Forecast, By Treatment 15.15.1. Surgery 15.15.1.1. Abdominal hysterectomy 15.15.1.2. Vaginal hysterectomy 15.15.2. Chemotherapy 15.15.3. Suction dilation and curettage (D&C) 15.15.4. Radiation Therapy 15.16. Mexico Gestational Trophoblastic Disease Market Forecast, By End User 15.16.1. Hospital and clinics 15.16.2. Diagnostic centers 15.16.3. Others 15.17. Mexico Gestational Trophoblastic Disease Market Forecast, By Type 15.17.1. Hydatidiform mole 15.17.1.1. Complete 15.17.1.2. Partial 15.17.1.3. Invasive 15.17.2. Choriocarcinoma 15.17.3. Placental-site trophoblastic tumor 15.17.4. Epithelioid trophoblastic tumor 15.17.5. Others 15.18. Rest of South America Gestational Trophoblastic Disease Market Forecast, By Treatment 15.18.1. Surgery 15.18.1.1. Abdominal hysterectomy 15.18.1.2. Vaginal hysterectomy 15.18.2. Chemotherapy 15.18.3. Suction dilation and curettage (D&C) 15.18.4. Radiation Therapy 15.19. Rest of South America Gestational Trophoblastic Disease Market Forecast, By End User 15.19.1. Hospital and clinics 15.19.2. Diagnostic centers 15.19.3. Others 15.20. Rest of South America Gestational Trophoblastic Disease Market Forecast, By Type 15.20.1. Hydatidiform mole 15.20.1.1. Complete 15.20.1.2. Partial 15.20.1.3. Invasive 15.20.2. Choriocarcinoma 15.20.3. Placental-site trophoblastic tumor 15.20.4. Epithelioid trophoblastic tumor 15.20.5. Others 15.21. South America Gestational Trophoblastic Disease Market Attractiveness Analysis 15.21.1. By Treatment 15.21.2. By End User 15.21.3. By Type 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Hikma Pharmaceuticals PLC. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Pfizer Inc. 16.3.3. Bristol-Myers Squibb Company 16.3.4. Antares Pharma 16.3.5. Mylan N.V. 16.3.6. Novartis AG 16.3.7. Teva Pharmaceutical Industries Ltd. 16.3.8. BP Pharmaceuticals Laboratories Company 16.3.9. Fresenius Kabi AG 16.3.10. Accord Healthcare, Inc. 16.3.11. Eli Lilly and Company 16.3.12. Sanofi 16.3.13. Bayer AG 16.3.14. Amgen Inc 16.3.15. Merck 17. Primary Key Insights

About This Report

Report ID66040
Category Healthcare
Published DateJuly 2020
No of Pages189
Contact Us